Piramal Pharma Delivers a Dose of Growth: Q4 Profits Surge, Revenue Climbs

Piramal Pharma Limited disclosed its quarter-end March 2025 financial performance, which remained strong with a high revenue and profitability growth. The company saw a consolidated revenue from operations at ₹2,754 crore (₹27.54 billion), which rose by 8% from the corresponding quarter last year. The growth was mainly led by strong demand in its Contract Development and Manufacturing Organization (CDMO) business, which continued to drive the company's performance.

 

Net profit in the March quarter jumped to ₹154 crore (₹1.54 billion) on a record 52% year-on-year growth. The operational efficiency focus of the company and its capability to leverage high-value opportunities in the pharma space find expression in the spurt in profitability.

 

Management noted that the enhanced performance is fueled by strategic investment in capacity and quality improvement and a diversified product platform that met changing market needs. The company is confident in maintaining this growth momentum with additional efforts to improve its global reach and expand its services in strategic markets.

 

The company's robust quarterly performance reflects its ability to withstand and adapt to an uncertain industry environment, setting it up for continued success in the upcoming fiscal year.

 

Source: Business Upturn